基于基质生物标志物识别预后不良且免疫治疗获益有限的pMMR/MSS与dMMR/MSI结直肠癌
本研究采用多组学方法整合单细胞RNA测序、计算性细胞解卷积和蛋白水平评估,结合体内外临床前模型,刻画与结直肠癌进展和治疗耐药相关的基质细胞群体。回顾性分析多个队列超过3000例患者样本,识别出表达CTHRC1的癌症相关成纤维细胞(CAF)亚群,与TGF-beta信号增强及早期和晚期疾病的不良临床结局相关。CTHRC1(+) CAF可将dMMR/MSI和pMMR/MSS肿瘤分层为免疫炎症型和免疫原性差亚型,并与MSI和MSS肿瘤对免疫检查点抑制剂的耐药相关,提示TGF-beta阻断联合免疫治疗的潜力。
要点
- CTHRC1(+) CAF与结直肠癌早期和晚期不良预后相关
- CTHRC1(+) CAF可将dMMR/MSI和pMMR/MSS肿瘤分为免疫炎症型与免疫原性差亚型
- CTHRC1(+) CAF与MSI和MSS肿瘤免疫检查点抑制剂耐药相关
核心结论
- CTHRC1(+) CAF是连接分子分型与诊断病理的临床相关生物标志物,支持将其评估纳入常规组织病理学流程(待前瞻性验证)。
研究设计与样本
- 采用多组学方法整合单细胞RNA测序、计算性细胞解卷积和患者肿瘤蛋白水平评估,并结合体内外临床前模型。
- 回顾性分析多个队列超过3000例患者样本。
主要发现
- CTHRC1(+) CAF与TGF-beta信号增强相关,并与早期和晚期疾病的不良临床结局相关。
- CTHRC1(+) CAF可将dMMR/MSI和pMMR/MSS肿瘤分层为免疫炎症型和免疫原性差亚型。
- 回顾性分析多个临床试验显示,CTHRC1(+) CAF与MSI和MSS肿瘤对免疫检查点抑制剂的耐药相关。
关键数值与推荐
- 回顾性分析超过3000例患者样本,识别出表达CTHRC1的CAF亚群。
- CTHRC1(+) CAF与dMMR/MSI和pMMR/MSS肿瘤的免疫炎症型与免疫原性差亚型分层相关。
临床怎么用
- CTHRC1(+) CAF评估有望纳入常规组织病理学流程,用于结直肠癌基质知情分层,尤其针对基质丰富、治疗耐药及pMMR/MSS治疗选择有限的患者。
- CTHRC1(+) CAF与免疫检查点抑制剂耐药相关,提示TGF-beta阻断联合免疫治疗可能具有治疗潜力。
局限性
- 研究为回顾性分析,CTHRC1(+) CAF评估纳入常规流程尚需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, with clinical progress limited by intratumoural cellular diversity and the absence of robust, informative markers. OBJECTIVE: Leveraging the heterogeneity of cancer-associated fibroblasts (CAFs) within the tumour microenvironment, this study aims to identify and evaluate candidate biomarkers to support patient stratification and improve prediction of therapeutic responses. DESIGN: We applied a multiomic approach integrating single-cell RNA sequencing, computational cell deconvolution and protein-level assessment from patient tumours, complemented by in vitro and in vivo preclinical models, to characterise stromal populations linked to CRC progression and treatment resistance. RESULTS: Retrospective analysis of over 3000 patient samples across multiple cohorts identified a distinct subset of CAFs expressing collagen triple helix repeat containing 1 (CTHRC1). CTHRC1(+) CAFs were associated with increased transforming growth factor-beta (TGF-beta) signalling and poor clinical outcomes in early and advanced disease stages. CTHRC1(+) CAFs enabled stratification of both mismatch repair-deficient/microsatellite instability (dMMR/MSI) and mismatch repair-proficient/microsatellite stability (pMMR/MSS) tumours into immune-inflamed and poorly immunogenic subtypes. Retrospective analysis of several clinical trials revealed that CTHRC1(+) CAFs are linked to resistance to immune checkpoint inhibitors in MSI and MSS tumours, suggesting therapeutic potential for combining TGF-beta blockade with immunotherapy. CONCLUSION: CTHRC1-expressing CAFs represent clinically relevant biomarkers that link molecular profiling with diagnostic pathology. Our findings support the potential incorporation of CTHRC1(+) CAF assessment into routine histopathological workflows, pending prospective validation, and suggest a framework for stroma-informed CRC stratification, particularly in patients with stroma-rich, treatment-resistant tumours and pMMR/MSS with limited therapeutic options.
引用
- Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C, et al. Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. Gut. 2026. PMID: 41980760. doi:10.1136/gutjnl-2025-336804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。